Addressing Hepatitis C and Hepatocellular Carcinoma: Current and Future Epidemics

描述（由申请人提供）：在美国，丙型肝炎病毒（HCV）相关死亡人数现已超过hiv相关死亡人数。在世界各地，丙型肝炎病毒在注射吸毒者中呈高流行。在男男性行为者（MSM）和从滥用处方阿片类药物过渡到非法注射阿片类药物的15-24岁人群中，新的急性丙型肝炎病毒感染暴发正在发生。慢性HCV感染患者中，20-25%会发展为肝脏疾病，表现为肝硬化、肝功能衰竭或肝细胞癌（HCC）。HCC的预后极差，丙型肝炎病毒是这类癌症的主要病因。最近在HCV预防和治疗方面的发现为扭转HCV、HCV/HIV合并感染和HCC发病率上升的趋势提供了一个很好的机会。这项研究将使用实施科学的方法——研究综合、数学建模和模拟以及比较效果分析——来确定如何最好地构成预防和控制丙型肝炎及其后果的干预组合，同时考虑到有限的资源和潜在的流行病学和社会网络特征。传播计划将广泛利用包括社会媒体在内的技术以及主要利益攸关方的指导。以下是我们的具体目标：综合a)从滥用处方阿片类药物到药物注射的转变，b) PWID和HIV+ MSM的HCV流行病学和预防，以及c)这两组HCV疾病的进展和治疗的证据，以得出HCV自然历史和传播模型的最佳估计。2. 使用基于agent的模型来估计个体和联合预防和治疗相关干预措施的扩大对PWID和HIV+MSM中HCV传播和自然史的影响。3. 确定针对特定预算和流行病学情景的干预措施组合：a)最大限度地减少急性和慢性丙型肝炎病毒感染，包括艾滋病毒/丙型肝炎病毒合并感染；b)最大限度地预防丙型肝炎病毒相关的HCC病例和其他严重后遗症；c)最大限度地提高预期寿命和质量调整后的预期寿命；d)减少健康差距。4. 与我们的传播咨询委员会合作，采用综合知识交流方法，向我们的目标受众（决策者、公共卫生和减少危害实践社区、艾滋病感染者和艾滋病毒阳性男男性行为者）提供知识和工具，以实施基于证据的丙型肝炎病毒控制战略或降低个人感染风险及其后果。本研究的主要目的是为指导美国和其他丙型肝炎病毒主要在PWID之间传播的国家分配稀缺的公共资源提供证据基础。这将通过综合、建模并将丙型肝炎病毒流行病学、预防和治疗方面的最新发展转化为优化人口健康的实用工具来实现。

DESCRIPTION (provided by applicant): Hepatitis C virus (HCV)-related deaths now exceed HIV-related deaths in the US. Throughout the world, HCV is hyperendemic in people who inject drugs (PWID). New outbreaks of acute HCV infection are unfolding in HIV-positive men who have sex with men (MSM) and in 15-24 year olds who have transitioned from abuse of prescription opioids to illicit opiate injection. In patients with chronic HCV infection, 20-25% wil develop liver disease which may manifest as cirrhosis, liver failure or hepatocellular carcinoma (HCC). The prognosis for HCC is extremely poor, and HCV is the chief etiologic agent for this type of cancer. Recent discoveries in HCV prevention and treatment provide a great opportunity to reverse the trend toward increasing rates of HCV, HCV/HIV co-infection, and HCC. This study will use the methods of Implementation Science - research synthesis, mathematical modeling and simulation, and comparative effectiveness analyses - to determine how best to constitute a portfolio of interventions for the prevention and control of HCV and its consequences while taking into limited resources and underlying epidemiologic and social network features account. A dissemination plan will make extensive use of technology, including social media, and guidance from key stakeholders. These are our specific aims: 1. Synthesize evidence characterizing a) transition from misuse of prescription opioids to drug injection, b) HCV epidemiology and prevention for PWID and HIV+ MSM, and c) progression and treatment of HCV disease in these two groups, to derive best estimates to populate our HCV natural history and transmission models. 2. Use agent-based modeling to estimate the effects of scale-up of individual and combined prevention- and treatment-related interventions on HCV transmission and natural history in PWID and HIV+MSM. 3. Determine the combination of interventions for particular budget and epidemiologic scenarios that a) minimizes acute and chronic HCV infections, including HIV/HCV co-infection, b) prevents the greatest number of cases of HCV-related HCC and other serious sequelae, c) maximizes life expectancy and quality- adjusted life expectancy and d) reduces health disparities. 4. In collaboration with our Dissemination Advisory Board, apply an integrated knowledge-exchange approach to providing our target audiences (policymakers, public health and harm reduction practice communities, PWID and HIV+MSM) with the knowledge and tools to implement evidence-based HCV control strategies or reduce personal risk of infection and its consequences. The broad objective of this study is to provide an evidence base to guide allocation of scarce public resources in the US and other countries where HCV is principally transmitted among PWID. This will be accomplished by synthesizing, modeling and translating very recent developments in HCV epidemiology, prevention and treatment into practical tools to optimize population health.